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Endothelin-1–Induced Interleukin-8 Production in Human Brain-Derived
Endothelial Cells Is Mediated by the Protein Kinase C and Protein
Tyrosine Kinase Pathways
By R. Zidovetzki, P. Chen, M. Chen, and F.M. Hofman
We have previously demonstrated that endothelin-1 (Et-1)
induces human central nervous system-derived endothelial
cells (CNS-EC) to produce and secrete the chemokine inter-
leukin 8 (IL-8). In the present study, we use specific inhibitors
and activators to elucidate the signal transduction pathways
involved in this process. Et-1–induced IL-8 production was
blocked by ETA receptor antagonist BQ610, but not by ETB
receptor antagonist BQ788, demonstrating that CNS-EC
activation is initiated by Et-1 binding to the ETA receptor. IL-8
mRNA expression is blocked by the protein kinase C inhibi-
tor bisindolylmaleimide or protein tyrosine kinase inhibitors,
genestein and geldanamycin, establishing the involvement
of the protein kinase C and protein tyrosine kinase pathways
in the activation process. The transcription factor, NF-kB, is
involved in Et-1 activation as determined by specific inhibi-
tors of translocation and direct analysis of DNA-binding
proteins. Neither inhibition nor activation of cAMP-depen-
dent protein kinase affected IL-8 production in the absence
or presence of Et-1. Similarly, no effect was observed upon
inhibition of protein phosphatases by okadaic acid. Thus, the
signal transduction process induced by Et-1 in CNS-EC,
leading to increased mRNA IL-8 expression, is initiated by
Et-1 binding to ETA receptor followed by subsequent activa-
tion of protein kinase C, protein tyrosine kinase, and NF-kB.
Because increased expression of Et-1 is associated with
hypertension and stroke and IL-8 is likely to be involved in
the accumulation of neutrophils causing tissue damage in
ischemic/reperfusion injury, identification of the mechanism
involved in the Et-1–induced increase in IL-8 production may
have significant therapeutic value.
r 1999 by The American Society of Hematology.
E
NDOTHELIN-1 (Et-1), a 21 amino acid peptide produced
by various cell types, including cerebral microvessels,
mediates vasoconstriction.1-3 This peptide was reported to be
increased in the plasma and cerebrospinal ﬂuid of patients with
hypertension, ischemic stroke, and subarachnoidal hemor-
rhage.4-7 Recent evidence demonstrated the pathologic signiﬁ-
cance of Et-1, as shown by the correlation between reduced Et-1
activity and decreased lesion size in reperfusion injury after
middle cerebral artery occlusion in rats.8 In the investigation of
the mechanisms of Et-1–mediated pathology, we found that this
peptide induced the production of the chemokine interleukin-8
(IL-8) in human central nervous system-derived endothelial
cells (CNS-EC).9
IL-8, an a chemokine, is produced predominantly by macro-
phages10-12 and endothelial cells13 and is characterized by its
potent and selective stimulatory effects on neutrophils, which
include chemotaxis,14 degranulation,15 respiratory burst,16 cell
shape change, exocytosis of secretory vesicles and azurophil
granules, expression of surface adhesion molecules, production
of superoxide and hydrogen peroxide reactive oxygen metabo-
lites,17,18 activation of 5-lipogenase,19 and the release of cell
matrix resorbing gelatinase and elastase.18 Studies have shown
that ischemic brain injury involves the initial inﬂux of neutro-
phils and that depletion of these cells or blocking their entry into
the brain leads to a signiﬁcant reduction in ischemic dam-
age.20,21 Et-1–induced IL-8 production may, therefore, be in-
volved in tissue damage during ischemia/reperfusion injury.
In the present work, we addressed the question of the
intracellular signal transduction pathway(s) used by Et-1 in
inducing increased IL-8 production in CNS-EC. Biological
effects of Et-1 are mediated by 2 types of Et receptors, ETA and
ETB, and involve multiple intracellular signal transduction
pathways, including activation of GTP-binding proteins, phos-
pholipases, protein kinases and phosphatases, and various
transcription factors (see Sokolovsky22 and Levin23 for re-
views). It has been suggested that a single ET receptor might
evoke diverse signaling pathways by activating multiple G
proteins; these may, in turn, activate single or multiple effectors,
forming a network in which various combinations of receptors
and G proteins interact to activate signal transduction pathways
optimized for physiological regulation in different cells.24
Moreover, the signal transduction upon Et-1 binding to its
receptor may differ among species and tissues. The data
presented here demonstrate that, in human CNS-EC, Et-1
induces increased IL-8 mRNA and protein production via ETA
receptor, protein kinase C (PK-C)–dependent and protein
tyrosine kinase (PTK)-dependent pathways without involve-
ment of the cAMP-dependent pathway.
MATERIALS AND METHODS
Reagents. The following reagents were purchased: Et-1 (Peninsula
Lab, Belmont, CA); ETA receptor antagonist, BQ610, and ETB receptor
antagonist, BQ788, from Alexis Corp (San Diego, CA); cAMP-
dependent protein kinase (PK-A) inhibitor, H-89, PK-C inhibitors,
bisindolylmaleimide-GF109203-X (GF) and Calphostin C; tyrosine
kinase inhibitors, genistein and geldanamycin, and inactive genistein
analog daidzen; and phosphoserine/phosphothreonine phosphatase in-
hibitor okadaic acid from Calbiochem (La Jolla, CA); dibutyryl-cAMP;
phorbol-12-myristate-13-acetate (PMA); 4-a-phorbol (inactive analog
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from Sigma (St Louis, MO). PK-C assay kits were purchased from
GIBCO Life Technologies (Gaithersburg, MD).
Cell culture. CNS-EC were derived from human brain as previ-
ously described in detail.25 Cells were cultured in RPMI-1640 medium
(GIBCO Life Technologies, Grand Island, NY) supplemented with 100
ng/mLendothelial cell growth factor Endogro (VECTEC,Albany, NY),
2 mmol/L L-glutamine, 10 mmol/L HEPES, 24 mmol/L sodium
bicarbonate, 300 USP units of heparin, 1% penicillin/streptomycin, and
10% fetal calf serum (FCS). Endogro-free, 0.1% FCS medium was used
24 hours before the experiment. The purity of CNS-EC (95%) was
conﬁrmed by immunocytochemical staining for von Willibrand factor
(vWF), glial ﬁbrillary acidic protein (GFAP) for astrocytes, and CD11b
for the macrophages, as previously described.25 Cells were used until
passage 4 or 5 only, because it was found that with increasing passage
number above 7, the intensity of vWF and g glutamyl transpeptidase
decreased.
RNase protection assay (RPA). The radioactively labeled RNA
antisense probes were prepared following the manufacturer’s protocol.
Using the In Vitro Transcription Kit (Pharmingen, San Diego, CA), 10
µL of [32P]UTP (3,000 Ci/mmol, 10 mCi/mL; NEN Research,Wilming-
ton, DE) and 1 µL GACU pool were added to the RPA Template Set
(HCK-5), a human chemokine multiprobe set including IL-8 and the
housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; Pharmingen); also included were T7 polymerase, dithiothrei-
tol (DTT), RNAsin, and transcription buffer, as suggested by the
manufacturer.The reaction was terminated by adding 2 µLof DNase for
30 minutes at 37°C. The probe was then extracted using Tris-saturated
phenol:chloroform:isoamylalcohol (25:24:1; GIBCO Life Technolo-
gies) and chloroform:isoamylalcohol sequentially and then was ethanol
precipitated. The radiolabeled RNApellet was air-dried and solubilized
with hybridization buffer. RNA from 2 to 3 3 106 cultured cells per
experimental group was isolated and prepared according to a modiﬁca-
tion of the acid phenol method using the Trizol reagent (Life Technolo-
gies) as speciﬁed by the manufacturer. Total RNA(10 µg) together with
6 3 105 cpm of probe was heat-denatured at 90°C and then hybridized
overnight at 56°C. Subsequently, the samples were treated with the
RNase cocktail, followed by proteinase K cocktails, and then precipi-
tated using ammonium acetate and ethanol. Air-dried samples were
solubilized in loading buffer, denatured at 90°C for 3 minutes, and then
placed on ice. The protected fragments were resolved in 5% acrylomide
8 mol/L urea gel (24 cm length); the gel was dried and exposed using
Hyper ﬁlm (Amersham Life Science,Arlington Heights, IL) at 270°C .
The protected bands were observed for IL-8 (181 bp) and GAPDH (96
bp). The data are presented as the ratios of the spectrophotometric
densities of IL-8 to GAPDH bands. The manufacturer’s recommended
yeast tRNA negative and positive controls were included in every RPA
experiment.
Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis.
Endothelial cells were treated and total RNA was isolated as described
above.To synthesize cDNA, 1 µg of denatured total RNAwas incubated
in 20 µL of reaction buffer (5 mmol/L MgCl2, 50 mmol/L KCl, 10
mmol/LTris-HCl,pH8.3)with2.5µmol/Loligo(dT)primerandmurine
leukemia virus reverse transcriptase (RT; 2.5 U/mL), which was
purchased as an RT-PCR kit (Perkin-Elmer, Foster City, CA). The
reverse transcription reaction was performed in 1 cycle: 42°C for 20
minutes,99°Cfor5minutes,and5°Cfor5minutes.PCRreactionswere
performed using 5 µLof cDNA, which was diluted 1:4 for ETA and ETB
receptors and 1:10 for b-actin in the presence of the reaction buffer, a
0.3 µmol/Lconcentration of each primer (Clontech, PaloAlto, CA), and
2 . 5Uo ftaq polymerase (Perkin-Elmer) in a total volume of 50 µL.
These dilution factors were based on the log-linear relationship between
the mRNA and the signal intensity of the PCR product. The PCR
reaction was performed as follows: 94°C for 1 minute and 45 seconds (1
cycle); 94°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30
seconds (32 cycles); and 72°C for 6 minutes and 4°C for 5 minutes (1
cycle). PCR analysis was performed using the human ETA receptor
primers (sense primer [58], 58AGC TTC CTG GTT ACC ACT CAT
CAA 38; and antisense primer [38], 58 TCAACATCT CAC AAG TCA
TGA G 38) and ETB receptor primers (sense [58], 58 CGA GCT GTT
GCT TCT TGG AGT AG 38; and antisense [38], 58 ACG GAA GTT
GTC ATA TCC GTG ATC 38). The sizes of the ETA and ETB receptor
PCR products are 714 and 701 bp, respectively. The human b-actin
primer, used as the control, was the following: sense primer (58), 58
GTG GGG CGC CCC AGG CAC CA 38; and antisense primer (38), 58
CTC CTT AAT GTC ACG CAC GAT TTC 38. The size of the PCR
product is 548 bp. The reverse transcriptase and PCR reactions were
performed in DNA thermal cycles (Perkin-Elmer Gene Amp PCR
system 2400). Ten-microliter PCR products were electrophoresed
through a 1.5% agarose gel and visualized by ethidium bromide
staining. The gel pattern was documented using the signal analytic
system and the band intensities were measured using the IP Lab gel
program (BT Scientiﬁc Technologies, Carlsbad, CA).
PK-C assay. Endothelial cells were treated as described in the
previous sections. The PK-C assays were performed using PK-C assay
kits obtained from GIBCO Life Technologies. Brieﬂy, the experimental
treatments were terminated by replacing the medium with the cell
extraction buffer (20 mmol/L Tris, 0.5 mmol/L EDTA, 0.5 mmol/L
EGTA, and 25 µg/mL each of aprotinin and leupeptin, pH 7.5) at room
temperature. The cells were then homogenized with a precooled dounce
homogenizer and the cytosol and membrane fractions were separated by
centrifugation (10,000g for 30 minutes) at 4°C. The supernatants were
collected as the cytosol fraction. The pellets were resuspended in 0.5
mL of extraction buffer with the detergent (1% NP-40). Membrane
fractions were obtained by centrifugation (10,000g for 10 minutes at
4°C) and collecting the supernatants. PK-C in both membrane and
cytosol fraction was partially puriﬁed by ion exchange chromatography
(DE-52 cellulose column). The determinations of PK-C activity in the
cytosol and membrane fractions were performed according to the
manufacturer’s instructions. The speciﬁc PK-C substrate was a syn-
thetic peptide from myelin basic protein (amino acids 4-14) with an
acetylated N-terminal glutamine, and the speciﬁc inhibitor was a
peptide (amino acids 19-36) derived from the same protein that binds to
the pseudo substrate region of the regulatory domain.The speciﬁc PK-C
activity was determined as the difference between phosphorylation of
the PK-C speciﬁc substrate in the absence or presence of the speciﬁc
PK-C inhibitor. The data are presented as ratios of the membrane and
the total (cytosol 1 membrane) PK-C activities.
Electrophoretic mobility shift assay (EMSA). CNS-EC were grown
to conﬂuence in 100-mm Petri dishes (107 cells/dish), treated with Et-1
(1028 mol/L), with tumor necrosis factor (TNF; 10 pg/mL), or left
untreated for 1 hour. Cells were then washed twice with ice-cold
phosphate-buffered saline (PBS), scraped in 15 mL of PBS/plate, and
centrifuged at 1,200 rpm for 10 minutes at 4°C. Cell pellets were then
resuspended in 400 µL of buffer A (10 mmol/L HEPES [pH 7.9], 1.5
mmol/L MgCl2, 10 mmol/L KCl, 0.5 mmol/L DTT, 0.5 mmol/L
phenylmethyl sulfonyl ﬂuoride [PMSF], 2 µg/mL leupeptin, and 2
µg/mL antipain) and placed on ice for 10 minutes; NP-40 (4%) was
added to each tube to reach a ﬁnal concentration of 0.1%. The tubes
were vortexed and centrifuged at 14,000 rpm for 30 seconds at 4°C, and
the supernatants were removed. The nuclear pellet was resuspended in
50 µL of buffer C (20 mmol/L HEPES, 25% glycerol, 1.5 mmol/L
MgCl2, 300 mmol/L NaCl, 0.25 mmol/L EDTA, 0.5 mmol/L PMSF, 2
µg/mLleupeptin, and 2 µg/mLantipain), vortexed, and placed on ice for
20 minutes. Samples were centrifuged at 14,000 rpm for 10 minutes at
4°C. Protein concentrations were determined using the Bio-Rad protein
assay kit (Bio-Rad Laboratories, Hercules, CA) with bovine serum
albumin as the standard. Nuclear extracts were diluted to 20 µg/µL with
buffer C, aliquoted, and stored at 2120°C. EMSAwas performed using
Gel Shift Systems (Promega, Madison, WI). The double-stranded
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and AP-1 used in this assay were commercially available (Promega).
The NF-kB binding site oligonucleotide was end-labeled with
[g-32P]ATP (ICN Pharmaceuticals Inc, Costa Mesa, CA) by incubation
with T4 Polynucleotide Kinase (Promega) at 37°C for 10 minutes. The
labeled probe was separated from unincorporated nucleotide using G-25
spin columns (Amersham Pharmacia Biotech, Piscataway, NJ). Nuclear
extracts (20 µg) were incubated with 10,000 cpm of labeled probe in a
binding buffer containing 10 mmol/LTris-HCl (pH 7.5), 4% glycerol, 1
mmol/LMgCl2, 0.5 mmol/LEDTA, 0.5 mmol/LDTT, 50 mmol/LNaCl,
0.05 mg/mL poly(dI-dC).(dI-dC) for 30 minutes at 4°C. Unlabeled
speciﬁc (NF-kB) or nonspeciﬁc (AP-1) binding site competitors, at
100-fold excess, were added to the reaction at this time to serve as
controls. Reaction products were analyzed by electrophoresis using 5%
nondenaturing polyacrylamide gels (0.53 Tris-borate-EDTA buffer) at
4°C for 2 hours. Gels were vacuum-dried and exposed to x-ray ﬁlm for
1 or 2 days.
Statistics. Values were presented as the mean 6 standard error of
the mean (SEM), unless otherwise stated. Statistical signiﬁcance was
evaluated using the unpaired Student’s t-test or ANOVA followed by
Bonferroni’s test using ProStat software (Poly Software International,
Salt Lake City, UT); P , .05 was considered signiﬁcant.
RESULTS
Both ETA and ETB receptors are expressed by CNS-EC.
Et-1 action can be mediated via 2 main types of endothelin
receptor, ETA or ETB. It was originally postulated that EC
predominantly express ETB receptors26; however, the presence
of ETA receptors on the surface of human CNS-EC has been
reported.27 The RT-PCR results using speciﬁc ETA and ETB
receptor probes on 3 different primary CNS-EC cell cultures are
shown in Fig 1; these data demonstrate the expression of mRNA
for both receptor types by human CNS-EC. In contrast, human
umbilical vein endothelial cells (HUVECs) expressed only the
ETB receptor mRNA(Fig 1).
Et-1 activation in CNS-EC is mediated by the ETA receptor.
The effect of Et-1 on IL-8 secretion by human CNS-EC has
been previously reported.9We demonstrated that cells incubated
with an optimal concentration of Et-1 (100 nmol/L) for 1 hour
exhibited an upregulation of IL-8 mRNA expression; Et-1–
induced IL-8 protein was detected within 24 hours. To ascertain
the identity of the functional Et-1 receptor type(s) in CNS-EC
for IL-8 mRNA expression, we used a speciﬁc ETA receptor
antagonist,BQ610,orETBreceptorantagonist,BQ788,concomi-
tantly with Et-1. Cells were pretreated with the Et-1 receptor
antagonists for 20 minutes, followed by incubation with Et-1 for
1 hour; subsequently, IL-8 mRNAwas analyzed using the RPA.
The data for this and all other ﬁgures were calculated as the
ratios of IL-8 mRNA to GAPDH mRNA and are presented in
graphic form as relative mRNA values. Concentrations of
receptor antagonists, ranging from 200 nmol/L to 1 µmol/L,
were previously tested. Figure 2 demonstrates that treatment
with BQ610 at the lowest concentration (200 nmol/L) com-
pletely abolished the IL-8 mRNA increase by Et-1, whereas
BQ788 (200 nmol/L) had no effect. BQ610 and BQ788, at the
highest concentration (1 µmol/L), gave essentially identical
results. These data demonstrate that Et-1 activation in CNS-EC
is mediated by ETA receptor. The data are representative of 3
experiments.
PK-A–dependent pathway is not involved in Et-1–induced
IL-8 production. We have previously observed that Et-1
activates PK-A in human CNS-EC,27a and others have shown
that agents which increase cAMP increase IL-8 protein produc-
tion.28 We therefore tested the effects of PK-A activation or
inhibitiononEt-1–inducedIL-8productioninCNS-EC.Conﬂu-
ent cultures of CNS-EC were treated with Et-1 (100 nmol/L)
alone or pretreated with the speciﬁc PK-A inhibitor, H-89 (0.5
µmol/L), or the PK-A–activating cAMP analog dibutyryl-
cAMP (dBu-cAMP; 300 µmol/L) for 30 minutes, followed by
the addition of Et-1 for 1 hour (Fig 3). The results show that
direct activation of PK-A by dBu-cAMP did not affect IL-8
mRNA expression; moreover, H-89 and dBu-AMP treatments
did not modify the Et-1–induced IL-8 mRNAsynthesis, demon-
strating that the PK-A–dependent pathway is not involved in
this effect of Et-1.
Et-1 increases PK-C activity. The time course of the effect
of 100 nmol/L Et-1 on membrane PK-C activity in CNS-EC is
shown on Fig 4.The increase in PK-C activity was signiﬁcant at
2 minutes, reached a maximum at 10 minutes, sharply de-
creased by 20 minutes, and thereafter slowly decreased to the
longest observed time of 60 minutes, when the activity was still
above the control levels (Fig 4). The effect was completely
inhibited by the presence of GF (1 µmol/L).
Involvement of PK-C in increased IL-8 mRNA expression.
Previous studies have reported that the PK-C–associated signal
transduction pathway may regulate IL-8 production in either a
positive or negative manner, depending on the cell type and the
stimulus involved.29-31 To test the involvement of the PK-C–
dependent signal transduction pathway in Et-1–induced IL-8
mRNA expression, human CNS-EC were treated with Et-1 as
described above or incubated with the speciﬁc PK-C inhibitor
GF (1 µmol/L) 30 minutes before exposure to Et-1. The results
in Fig 5 show that preincubation of the cells with GF completely
eliminated the Et-1–induced increase in IL-8 mRNA. Similar
results were obtained with another PK-C inhibitor, calphostin C
(data not shown). To determine the relevance of the early PK-C
activation on the delayed IL-8 response, GF was added to the
cells 30 minutes after the initial exposure of the cells to Et-1; the
experiment was terminated after 1 hour of incubation, as
described previously. The data showed that the addition of GF
30 minutes after exposure to Et-1 had no effect on Et-1–induced
IL-8 mRNA expression (Fig 5), demonstrating that the early
increase in PK-C activity is necessary and sufficient for IL-8
mRNAinduction.
PTK pathway involved in Et-1 activation. We then exam-
ined the role of PTKs in Et-1–induced IL-8 mRNA expression
Fig 1. The expression of ETA and ETB receptors on CNS-EC and
HUVECs. RNA from cells from 3 different CNS-EC cultures and 1
sample of HUVECs was extracted and examined using PCR primers
for ETA (lanes 1 through 4), ETB (lanes 5 through 8) receptors, and
b-actin (lanes 9 through 12). The CNS-EC are grouped in lanes 1, 5,
and 9; 2, 6, and 10; and 3, 7, and 11. HUVEC RNA is shown in lanes 4, 8,
and 12. M designates the marker lane.
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(37 µmol/L) for 15 minutes before the addition of Et-1; after 1
hour of incubation, the experiment was terminated as described
above. The data in Fig 6A and B demonstrated that genistein
completely abolished the effect of Et-1, whereas the inactive
genistein analog daidzen (39 µmol/L) had no such effect.
Another PTK inhibitor, geldanamycin (178 nmol/L), which
speciﬁcally inhibits p60 c-src tyrosine kinase, also inhibited
Et-1–induced IL-8 mRNA expression (Fig 6C). From these
experiments, it was apparent that both the PK-C and PTK
pathways were involved in this Et-1 signaling pathway. Further
studies were performed to determine whether the effects of
PK-C–dependent or PTK-dependent pathways in IL-8 mRNA
induction were sequential or parallel. As shown in Fig 7,
treatment of CNS-EC for 1 hour with PK-C activator PMA (1
nmol/L) upregulated IL-8 mRNAexpression; the inactive PMA
analog 4-a-phorbol had no effect (data not shown). Pretreat-
ment (15 minutes) with the PTK inhibitor genistein completely
abolished the effect of PMA, demonstrating that PTK activation
is downstream from PK-C activation in this process.
Protein phosphorylation in the signaling process is regulated
by both protein kinases and phosphatases. We tested the role of
serine/threonine phosphorylation on IL-8 mRNA expression in
CNS-ECbytreatingthecellswithokadaicacid,aphosphoserine/
phosphothreonine phosphatase inhibitor. CNS-EC were treated
with okadaic acid (10 nmol/L) alone or 30 minutes before Et-1
treatment; the cells were then incubated for 1 hour and analyzed
for IL-8 mRNAexpression. Figure 8 shows that okadaic acid at
10 nmol/Ldid not modify the IL-8–inducing effect of Et-1.
NF-kB is involved in Et-1–induced IL-8 synthesis. Finally,
we examined the involvement of transcription factor NF-kBi n
the mechanism of Et-1 action. The cells were pretreated for 30
minutes with NF-kB inhibitor PDTC and then with Et-1 as
described above. The results in Fig 9 show that PDTC inhibited
the Et-1–induced IL-8 mRNA increase in a concentration-
dependent manner; complete inhibition was achieved at 30
µmol/L of PDTC. To directly determine whether NF-kBi s
involved in Et-1 activation, the gel shift assay was performed.
Figure 10 demonstrates that Et-1activation of CNS-EC induced
NF-kB translocation and binding to DNA (lane 4). In the
presence of the unlabeled speciﬁc competitor, the shift was not
observed (lane 5); however, in the presence of the unlabeled
nonspeciﬁc binding site to transcription factor AP-1, the shift
was apparent. TNF activation of CNS-EC served as the positive
control. These studies indicate that NF-kB is responsible, at
least in part, for the Et-1–induced IL-8 production.
DISCUSSION
This work extended our ﬁndings that Et-1 induced an
upregulation of IL-8 mRNA expression and protein production
in human CNS-EC9 by focusing on the elucidation of the
intracellular signal transduction pathway(s) involved in this
process. We ﬁrst identiﬁed the speciﬁc receptor class respon-
sible for the Et-1–induced IL-8 production in CNS-EC. Two
distinct ET receptor subtypes, ETA and ETB, have been cloned
and sequenced.32 EC in a variety of tissues, ie, liver, kidney, and
brain, possess predominantly ETB receptors, which mediate
vasodilation by the generation of endothelium-derived relaxing
A
Fig 2. The effect of Et receptor antagonists. The
CNS-EC were pretreated with 200 nmol/L ETA recep-
tor antagonist, BQ610, or 200 nmol/L ETB receptor
antagonist, BQ788, for 20 minutes, followed by 1
hour of incubation with 100 nmol/L Et-1. In all of the
experiments presented, cells were treated with Et-1
for 1 hour. Subsequently, RNA was isolated from the
cells, and the RPA was performed. The results are
visualized by autoradiography; protected fragments
corresponding to IL-8 (181 bp) and GAPDH (96 bp) are
shown (A). The data in this and subsequent figures
were calculated as the ratios of IL-8 mRNA to GAPDH
mRNA and are presented relative to the control
values (B). The data presented are representative of 1
of 3 replicate experiments performed. The error bars
represent the SEM.
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nantly found in peripheral tissues, especially in vascular smooth
muscle cells mediating vasoconstriction. Both types of recep-
tors were found in rat and human brain EC,34-36 where they
mediate distinct functions. In agreement with the previous
reports, we have found the expression of both receptor types by
human CNS-EC. Furthermore, our present results showed that
ETA antagonist BQ610, but not ETB antagonist BQ788, inhibits
the observed effect of Et-1 effect, demonstrating that here the
ETA receptor is responsible for the initiation of the signal
transduction pathway to IL-8 production.
We next examined the role of speciﬁc signal transduction
pathways involved in Et-1–induced IL-8 production. It had
been previously reported that increased intracellular cAMP
levels caused increased IL-8 protein production in human
monocytes,28 whereas in the present work inhibition of PK-Aby
H-89 did not affect Et-1–induced IL-8 increase. Our results
agree with those of others30 who showed that, in human colon
epithelial cells, H-89 did not affect the IL-1–induced or
TNF-induced IL-8 production; and this chemokine was not
stimulated by forskolin, an agent that upregulates cAMP. In
addition, White and Lee37 reported that inhibition of PK-A did
not affect IL-1–induced IL-8 production by HUVEC. It is
interesting to note that we have previously found that Et-1
A
Fig 3. The role of cAMP-dependent pathway. The CNS-EC were
pretreated for 30 minutes with 0.5 mmol/L of the specific PK-A
inhibitor, H-89, or with 300 mmol/L of PK-A–activating cAMP analog
dBu-cAMP, followed by 1 hour of incubation with 100 nmol/L Et-1.
The autoradiographic (A) and graphic data (B) are presented as
described in Fig 2.
Fig 4. PK-C activity of CNS-EC as a function of the duration of Et-1
treatment. Et-1 concentration was 100 nmol/L, and the GF concentra-
tion was 1 mmol/L. PK-C activity is expressed as a ratio of the
membrane to total activities. Solid line, in the absence of GF;
broken line, in the presence of GF.
A
Fig 5. The role of PK-C–dependent pathway. In 1 group (GF1Et),
the cells were pretreated for 30 minutes with 1 mmol/L of the specific
PK-C inhibitor GF, followed by 1 hour of incubation with 100 nmol/L
Et-1. In another group (Et1GF), GF was added 30 minutes after the
initial treatment with Et-1. Cells were treated with Et-1 for a total of 1
hour. The autoradiographic (A) and graphic data (B) are presented as
described in Fig 2.
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activity in human CNS-EC.27a However, the present study
demonstrates that, in CNS-EC, PK-A activation is not relevant
for the Et-1 induction of IL-8 production.
Our results demonstrated rapid activation of PK-C by Et-1.
However, activation of PK-C may increase or attenuate IL-8
production, depending on both the cell type and stimulus
involved. Thus, PMA induced IL-8 production in HUVEC,37,38
human keratinocytes,29 human colon epithelial cells,30 and
human CNS-EC (this study). In HUVEC and human colon
epithelial cells, the PK-C inhibitors staurosporine or calphostin
inhibited PMA-induced37 or thrombin-induced38 IL-8 expres-
A C
Fig 6. The role of PTKs. The cells were pretreated
for 15 minutes with the specific PTK inhibitor geni-
stein (37 mmol/L) or the inactive genistein analog
daidzen (39 mmol/L), followed by 1 hour of incuba-
tion with 100 nmol/L Et-1; data are shown in an
autoradiograph (A) and graphically (B). CNS-EC were
pretreated with geldanamycin (178 nmol/L) for 16
hours, followed by 1 hour of incubation with 100
nmol/L Et-1. The autoradiograph of the RPA for IL-8
mRNA is shown (C).
A
Fig 7. Sequential activation of PK-C and PTK. The
cells were treated for 1 hour with 1 nmol/L of the
PK-C activator PMA or pretreated for 15 minutes
with the specific PTK inhibitor genestein (37 mmol/L)
or the inactive genestein analog daidzen (39 mmol/
L), followed by the PMA treatment. The autoradio-
graphic (A) and graphic data (B) are presented as
previously described.
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induced IL-8 production,30,37,38 showing that, even in identical
cell populations, the same functional response can be achieved
by different stimuli via distinct pathways. PK-C inhibitors also
block IL-8 mRNAexpression in HL-6039 and in ﬁbroblasts.31 In
the present study, we showed that human CNS-EC require
PK-C activation for Et-1–induced IL-8 mRNA expression, and
this activation takes place within the ﬁrst 30 minutes of
stimulation. The addition of the PK-C inhibitor GF 30 minutes
after Et-1 stimulation clearly demonstrated that the short burst
of PK-C activity induced by Et-1 was necessary and sufficient
for the upregulation of IL-8 mRNAexpression.
Similarly to PK-C, the role of PTK in inducing the IL-8
production is cell type-dependent. Inhibition of PTK by various
agentsdidnotaffectIL-1–inducedIL-8productioninHUVEC,37
whereas PTK inhibitors did inhibit IL-8 gene induction in a
variety of other model systems: by platelet activation factor in
ﬁbroblasts,31 by IL-1 or TNF in human colon epithelial cells,30
and by IL-1 in human bone marrow stromal cells.40 The data
here show that PTK is involved in the upregulation of Et-1–
induced IL-8 mRNA expression in human CNS-EC. Further-
more, we demonstrated that, in these cells, PTK is directly
activated by PK-C and PMA-induced IL-8 increase is blocked
by PTK inhibitor genistein, which places PK-C activation
upstream to PTK in the activation process.
The inhibition of phosphoserine/phosphothreonine phospha-
tase in IL-8 mRNA expression is also cell type-dependent.
Sonoda et al41 found that inhibition of phosphatases by okadaic
acid or vanadate dramatically increased IL-8 production by
HL-60, but not by primary monocytes. In the experiments
presented here, okadaic acid alone did not induce IL-8 mRNA
increase in CNS-EC; furthermore, the presence of okadaic acid
did not affect the Et-1–induced mRNA increase, demonstrating
that, in the present system at the concentration of okadaic acid
used here (10 nmol/L), at least phosphoserine/phosphothreo-
nine phosphatase 2Ais not involved in the observed effects.
We next examined the role of the transcription factor, NF-kB,
in the Et-1–induced IL-8 response. The IL-8 gene has several
potential binding sites for c-jun,N F - kB, AP2, glucocorticoid
receptor, and NF-IL-6.42 It had been suggested that, depending
on the cell line, either the combination of NF-kB and AP-1 or
NF-kB and NF-IL6 is required.43 It has indeed been shown that,
in gastric cell lines, NF-kB and AP-1 are sufficient for the IL-8
gene activation,44 whereas in the ﬁbrosarcoma line the impor-
tant factors are C/EBP and NF-kB,42 and in epithelial Caco2
cells NF-kB, AP-1, and C/EBP.45 In the present work, we
demonstrated that NF-kB activation is also involved in the
A
Fig 8. The role of protein phosphatases. The CNS-EC were pre-
treated for 30 minutes with 10 nmol/L of the phosphatase inhibitor
okadaic acid, followed by 1 hour of incubation with 100 nmol/L Et-1.
The autoradiographic (A) and graphic data (B) are presented as
previously described.
A
Fig 9. Inhibitors of NF-kB block Et-1 activation. Cells were pre-
treated for 30 minutes with increasing concentrations of PDTC,
followed by 1 hour of incubation with 100 nmol/L Et-1. The autoradio-
graphic (A) and graphic data (B) are presented.
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other transcriptional factors are also likely to be involved.
In conclusion, this study described, in part, the complex
network of intracellular signal transduction pathways used by
Et-1 to effect IL-8 production. Both the elicited cellular
responses and signal transduction mechanisms used in perform-
ing a particular response are cell type-dependent, necessitating
the detailed investigation of the pathway(s) involved for each
speciﬁc response (eg, IL-8 production) and each speciﬁc cell
type (eg, human CNS-EC) and stimulus. In the present work,
we demonstrated that the Et-1– induced IL-8 mRNAincrease in
human CNS-EC is initiated by binding of Et-1 to the ETA
receptor, followed by the subsequent activation of PK-C, PTK,
and NF-kB. There are likely to be other enzymes and factors
involved in the signal transduction pathway leading to IL-8
production. However, it is only by the systematic characteriza-
tion of the components of this pathway that new therapeutic
targets for the regulation of this chemokine can be identiﬁed.
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